

# Anne Peters Harmel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7429674/publications.pdf>

Version: 2024-02-01

143  
papers

22,952  
citations

24978

57  
h-index

11030

137  
g-index

148  
all docs

148  
docs citations

148  
times ranked

19722  
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. <i>Diabetes Care</i> , 2012, 35, 1364-1379.	4.3	3,077
2	Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2015, 38, 140-149.	4.3	2,326
3	Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2013, 369, 145-154.	13.9	2,294
4	Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes: One-year results of the Look AHEAD trial. <i>Diabetes Care</i> , 2007, 30, 1374-1383.	4.3	1,369
5	Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 1481-1486.	4.3	1,342
6	Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association. <i>Diabetes Care</i> , 2014, 37, 2034-2054.	4.3	727
7	Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. <i>Diabetes Care</i> , 2015, 38, 1687-1693.	4.3	645
8	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , 2015, 58, 429-442.	2.9	598
9	Exercise management in type 1 diabetes: a consensus statement. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 377-390.	5.5	588
10	9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes 2022. <i>Diabetes Care</i> , 2022, 45, S125-S143.	4.3	534
11	Diabetes Care for Emerging Adults: Recommendations for Transition From Pediatric to Adult Diabetes Care Systems. <i>Diabetes Care</i> , 2011, 34, 2477-2485.	4.3	477
12	6. Glycemic Targets: Standards of Medical Care in Diabetes 2022. <i>Diabetes Care</i> , 2022, 45, S83-S96.	4.3	388
13	Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 2337-2348.	13.9	322
14	Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. <i>Diabetes Care</i> , 2017, 40, 1622-1630.	4.3	283
15	Real-Time Continuous Glucose Monitoring Among Participants in the T1D Exchange Clinic Registry. <i>Diabetes Care</i> , 2014, 37, 2702-2709.	4.3	278
16	Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study. <i>Diabetes Therapy</i> , 2018, 9, 583-612.	1.2	267
17	Severe Hypoglycemia and Diabetic Ketoacidosis in Adults With Type 1 Diabetes: Results From the T1D Exchange Clinic Registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3411-3419.	1.8	258
18	Understanding the sources of diabetes distress in adults with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 572-577.	1.2	253

#	ARTICLE	IF	CITATIONS
19	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. <i>Diabetes Care</i> , 2019, 42, 1147-1154.	4.3	249
20	The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2021, 44, 2589-2625.	4.3	244
21	REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes. <i>Diabetes Care</i> , 2017, 40, 538-545.	4.3	230
22	Trial to Examine Text Message-Based mHealth in Emergency Department Patients With Diabetes (TEXT-MED): A Randomized Controlled Trial. <i>Annals of Emergency Medicine</i> , 2014, 63, 745-754.e6.	0.3	224
23	An Overview of Metformin in the Treatment of Type 2 Diabetes Mellitus. <i>American Journal of Medicine</i> , 1997, 102, 99-110.	0.6	216
24	Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2397.	3.8	191
25	Prevalence of Detectable C-Peptide According to Age at Diagnosis and Duration of Type 1 Diabetes. <i>Diabetes Care</i> , 2015, 38, 476-481.	4.3	187
26	Impact of Intensive Lifestyle Intervention on Depression and Health-Related Quality of Life in Type 2 Diabetes: The Look AHEAD Trial. <i>Diabetes Care</i> , 2014, 37, 1544-1553.	4.3	178
27	5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: Standards of Medical Care in Diabetes 2022. <i>Diabetes Care</i> , 2022, 45, S60-S82.	4.3	177
28	Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. <i>Diabetes Care</i> , 2018, 41, 1970-1980.	4.3	170
29	Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3922-3937.	1.8	165
30	Relationship Between Fasting Plasma Glucose and Glycosylated Hemoglobin. <i>JAMA - Journal of the American Medical Association</i> , 1999, 281, 1203.	3.8	164
31	Long-Term Outcomes of a Web-Based Diabetes Prevention Program: 2-Year Results of a Single-Arm Longitudinal Study. <i>Journal of Medical Internet Research</i> , 2015, 17, e92.	2.1	157
32	Food and Park Environments: Neighborhood-level Risks for Childhood Obesity in East Los Angeles. <i>Journal of Adolescent Health</i> , 2007, 40, 325-333.	1.2	144
33	Impact of an Intensive Lifestyle Intervention on Use and Cost of Medical Services Among Overweight and Obese Adults With Type 2 Diabetes: The Action for Health in Diabetes. <i>Diabetes Care</i> , 2014, 37, 2548-2556.	4.3	144
34	HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study. <i>Diabetes Care</i> , 2018, 41, 1981-1990.	4.3	138
35	A Mobile Health Intervention for Inner City Patients with Poorly Controlled Diabetes: Proof-of-Concept of the TEXT-MED Program. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 492-496.	2.4	136
36	The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2021, 64, 2609-2652.	2.9	128

#	ARTICLE	IF	CITATIONS
37	Diabetes distress in adults with type 1 diabetes: Prevalence, incidence and change over time. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1123-1128.	1.2	126
38	Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 603-610.	4.3	126
39	Clinical Application of Emerging Sensor Technologies in Diabetes Management: Consensus Guidelines for Continuous Glucose Monitoring (CGM). <i>Diabetes Technology and Therapeutics</i> , 2008, 10, 232-246.	2.4	114
40	Translating the Diabetes Prevention Program into an Online Social Network. <i>The Diabetes Educator</i> , 2014, 40, 435-443.	2.6	111
41	Recommendations for Standardizing Glucose Reporting and Analysis to Optimize Clinical Decision Making in Diabetes: The Ambulatory Glucose Profile. <i>Journal of Diabetes Science and Technology</i> , 2013, 7, 562-578.	1.3	104
42	Incretin-Based Therapies: Review of Current Clinical Trial Data. <i>American Journal of Medicine</i> , 2010, 123, S28-S37.	0.6	97
43	Insulin Pump Risks and Benefits: A Clinical Appraisal of Pump Safety Standards, Adverse Event Reporting, and Research Needs. <i>Diabetes Care</i> , 2015, 38, 716-722.	4.3	95
44	The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes. <i>Diabetes Care</i> , 2017, 40, 171-180.	4.3	91
45	Diabetic Ketoacidosis With Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 532-538.	4.3	83
46	Let's Empower and Prepare (LEAP): Evaluation of a Structured Transition Program for Young Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2015, 38, 1412-1419.	4.3	79
47	Engagement and outcomes in a digital Diabetes Prevention Program: 3-year update. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000422.	1.2	79
48	A Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System for the Management of Adults With Diabetes. <i>Journal of the Endocrine Society</i> , 2017, 1, 1445-1460.	0.1	75
49	Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 904-911.	2.4	74
50	3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes 2022. <i>Diabetes Care</i> , 2022, 45, S39-S45.	4.3	74
51	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1226-1242.	1.3	69
52	Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: Results from the look AHEAD randomized trial. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 619-627.	3.1	68
53	Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 571-575.	2.4	68
54	Revisiting the oral glucose tolerance test criterion for the diagnosis of diabetes. <i>Journal of General Internal Medicine</i> , 2000, 15, 551-555.	1.3	67

#	ARTICLE	IF	CITATIONS
55	The Role of Farmersâ€™ Markets in Two Low Income, Urban Communities. <i>Journal of Community Health</i> , 2012, 37, 554-562.	1.9	67
56	Depression in Adults in the T1D Exchange Clinic Registry. <i>Diabetes Care</i> , 2014, 37, 1563-1572.	4.3	65
57	Male Anorgasmia Treated with Oxytocin. <i>Journal of Sexual Medicine</i> , 2008, 5, 1022-1024.	0.3	62
58	Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. <i>Diabetologia</i> , 2015, 58, 862-870.	2.9	62
59	Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. <i>Diabetologia</i> , 2020, 63, 229-241.	2.9	56
60	Beyond the Monofilament for the Insensate Diabetic Foot. <i>Diabetes Care</i> , 2011, 34, 1041-1046.	4.3	55
61	Intensive Weight Loss Intervention in Older Individuals: Results from the Action for Health in Diabetes Type 2 Diabetes Mellitus Trial. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 912-922.	1.3	52
62	Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. <i>Diabetes Care</i> , 2019, 42, 919-930.	4.3	51
63	Impact of Intensive Lifestyle Intervention on Disability-Free Life Expectancy: The Look AHEAD Study. <i>Diabetes Care</i> , 2018, 41, 1040-1048.	4.3	47
64	Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial. <i>Obesity</i> , 2020, 28, 1678-1686.	1.5	47
65	The Impact of Real-Time Continuous Glucose Monitoring in Patients 65 Years and Older. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 892-897.	1.3	44
66	The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3430.	1.7	44
67	Continuous Glucose Monitoring Pilot in Low-Income Type 1 Diabetes Patients. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 855-858.	2.4	41
68	Clinical and Economic Impact of a Digital, Remotely-Delivered Intensive Behavioral Counseling Program on Medicare Beneficiaries at Risk for Diabetes and Cardiovascular Disease. <i>PLoS ONE</i> , 2016, 11, e0163627.	1.1	41
69	Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A <i>post hoc</i> analysis of the AWARDâ€², â€²4 and â€²5 Trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1490-1498.		40
70	Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 1552-1559.	1.7	39
71	Immigration Disparities in Cardiovascular Disease Risk Factor Awareness. <i>Journal of Immigrant and Minority Health</i> , 2012, 14, 918-925.	0.8	38
72	The relationship of social support with treatment adherence and weight loss in Latinos with type 2 diabetes. <i>Obesity</i> , 2016, 24, 568-575.	1.5	38

#	ARTICLE	IF	CITATIONS
73	Clinical and Psychosocial Outcomes of a Structured Transition Program Among Young Adults With Type 1 Diabetes. <i>Journal of Adolescent Health</i> , 2017, 60, 212-218.	1.2	38
74	Four-Year Physical Activity Levels among Intervention Participants with Type 2 Diabetes. <i>Medicine and Science in Sports and Exercise</i> , 2016, 48, 2437-2445.	0.2	37
75	Objectively Assessed Physical Activity and Weight Loss Maintenance among Individuals Enrolled in a Lifestyle Intervention. <i>Obesity</i> , 2017, 25, 1903-1909.	1.5	36
76	The Look AHEAD Trial: Bone Loss at 4-Year Follow-up in Type 2 Diabetes. <i>Diabetes Care</i> , 2014, 37, 2822-2829.	4.3	33
77	Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis. <i>Journal of Medical Economics</i> , 2013, 16, 529-538.	1.0	31
78	Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis. <i>BMJ, The</i> , 2015, 351, h6223.	3.0	30
79	Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2632-2642.	2.2	30
80	Intensification of insulin therapy in patients with type 2 diabetes mellitus: An algorithm for basal-bolus therapy. <i>Annals of Medicine</i> , 2012, 44, 836-846.	1.5	29
81	Hypoglycemia in Older Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 765-771.	2.4	29
82	Healthcare Costs and Adherence Associated with Human Regular U-500 Versus High-Dose U-100 Insulin in Patients with Diabetes. <i>Endocrine Practice</i> , 2014, 20, 663-670.	1.1	27
83	Benefit of Continuous Glucose Monitoring in Reducing Hypoglycemia Is Sustained Through 12 Months of Use Among Older Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 424-434.	2.4	27
84	Patient Perspectives on Peer Mentoring. <i>The Diabetes Educator</i> , 2015, 41, 59-68.	2.6	26
85	Racial/ethnic and socioeconomic disparities in the use of newer diabetes medications in the Look AHEAD study. <i>The Lancet Regional Health Americas</i> , 2022, 6, 100111.	1.5	26
86	Mifepristone Treatment in Four Cases of Primary Bilateral Macronodular Adrenal Hyperplasia (BMAH). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6279-6290.	1.8	23
87	Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk. <i>Cleveland Clinic Journal of Medicine</i> , 2009, 76, S20-S27.	0.6	23
88	Cardiovascular health: associations with race/ethnicity, nativity, and education in a diverse, population-based sample of Californians. <i>Annals of Epidemiology</i> , 2013, 23, 388-394.	0.9	22
89	Implications of the Hemoglobin Glycation Index on the Diagnosis of Prediabetes and Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e130-e138.	1.8	22
90	Function and Emotion in Everyday Life With Type 1 Diabetes (FEEL-T1D): Protocol for a Fully Remote Intensive Longitudinal Study. <i>JMIR Research Protocols</i> , 2021, 10, e30901.	0.5	22

#	ARTICLE	IF	CITATIONS
91	Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000074.	1.2	21
92	The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 960-968.	4.3	21
93	Understanding bolus insulin dose timing: the characteristics and experiences of people with diabetes who take bolus insulin. <i>Current Medical Research and Opinion</i> , 2017, 33, 639-645.	0.9	20
94	Weight Loss Experiences of African American, Hispanic, and Non-Hispanic White Men and Women with Type 2 Diabetes: The Look AHEAD Trial. <i>Obesity</i> , 2019, 27, 1275-1284.	1.5	20
95	Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2440-2449.	2.2	20
96	Clinical and Behavioral Correlates of Achieving and Maintaining Glycemic Targets in an Underserved Population With Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 54-56.	4.3	19
97	Do Experiences Consistent With a Medical-Home Model Improve Diabetes Care Measures Reported by Adult Medicaid Patients?. <i>Diabetes Care</i> , 2014, 37, 2565-2571.	4.3	17
98	Resilient, Empowered, Active Living with Diabetes (REAL Diabetes) study: Methodology and baseline characteristics of a randomized controlled trial evaluating an occupation-based diabetes management intervention for young adults. <i>Contemporary Clinical Trials</i> , 2017, 54, 8-17.	0.8	17
99	Biosimilars and New Insulin Versions. <i>Endocrine Practice</i> , 2015, 21, 1387-1394.	1.1	16
100	Primary Care Medical Home Experience and Health-Related Quality of Life Among Adult Medicaid Patients with Type 2 Diabetes. <i>Journal of General Internal Medicine</i> , 2015, 30, 161-168.	1.3	16
101	Advances in Glucose Monitoring and Automated Insulin Delivery: Supplement to Endocrine Society Clinical Practice Guidelines. <i>Journal of the Endocrine Society</i> , 2018, 2, 1214-1225.	0.1	16
102	Diabetes Management For Low-Income Patients In Los Angeles: Two Strategies Improved Disease Control In The Short Term. <i>Health Affairs</i> , 2012, 31, 168-176.	2.5	15
103	"We Are All Gonna Get Diabetic These Days" <i>The Diabetes Educator</i> , 2014, 40, 648-658.	2.6	15
104	Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies. <i>Diabetes Care</i> , 2020, 43, 2713-2720.	4.3	15
105	Trends in diabetes-related visits to US EDs from 1997 to 2007. <i>American Journal of Emergency Medicine</i> , 2012, 30, 754-758.	0.7	14
106	Diabetes Empowerment Council: Integrative Pilot Intervention for Transitioning Young Adults With Type 1 Diabetes. <i>Global Advances in Health and Medicine</i> , 2018, 7, 216495611876180.	0.7	14
107	Do menopausal status and APOE4 genotype alter the long-term effects of intensive lifestyle intervention on cognitive function in women with type 2 diabetes mellitus?. <i>Neurobiology of Aging</i> , 2020, 92, 61-72.	1.5	12
108	The Affordable Care Act and Health Insurance Coverage Among People With Diagnosed and Undiagnosed Diabetes: Data From the National Health and Nutrition Examination Survey. <i>Diabetes Care</i> , 2019, 42, e179-e180.	4.3	11



#	ARTICLE	IF	CITATIONS
109	Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study. <i>Diabetes Care</i> , 2021, 44, 67-74.	4.3	10
110	Short and longer term outcomes of a diabetes disease management program in underserved Latino patients. <i>Current Medical Research and Opinion</i> , 2005, 21, 1935-1941.	0.9	7
111	GLP-1 Provoked Severe Hypoglycemia in an Individual With Type 2 Diabetes and a Benign Insulinoma. <i>Diabetes Care</i> , 2014, 37, e177-e178.	4.3	7
112	Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes. <i>Aging Clinical and Experimental Research</i> , 2014, 26, 115-121.	1.4	7
113	Comprehensive Pulmonary Safety Review of Inhaled Technosphere <sup>®</sup> Insulin in Patients with Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2020, 40, 973-983.	1.1	7
114	Re-emergence of another vaccine-preventable disease? Two cases of rubella in older adults. <i>Journal of Clinical Virology</i> , 2009, 46, 98-100.	1.6	6
115	Extended-Release Formulation and Medication Adherence. <i>Journal of General Internal Medicine</i> , 2020, 35, 354-356.	1.3	6
116	Integration of Diabetes Technology in Clinical Practice. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 69-77.	1.2	6
117	Antihypertensive Agents in Diabetic Patients. <i>Archives of Internal Medicine</i> , 1999, 159, 541.	4.3	5
118	Characteristics of youth with type 1 diabetes (T1D) with and without a parent with T1D in the T1D exchange clinic registry. <i>Journal of Diabetes</i> , 2016, 8, 834-838.	0.8	5
119	Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1083-1093.	2.2	5
120	Changes in mood and health-related quality of life in Look AHEAD 6 years after termination of the lifestyle intervention. <i>Obesity</i> , 2021, 29, 1294-1308.	1.5	5
121	Death and Medicine: A personal account. <i>American Journal of Medicine</i> , 1990, 89, 81-82.	0.6	4
122	Diabetes Empowerment Council (DEC): Development and Pilot Testing of an Innovative Mind-Body Group Intervention for Young Adults with Type 1 Diabetes. <i>Journal of Alternative and Complementary Medicine</i> , 2014, 20, A69-A69.	2.1	4
123	Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodium-Glucose Cotransporter 2 Inhibitor. <i>Diabetes Spectrum</i> , 2021, 34, 42-51.	0.4	4
124	Case Study 2. <i>The Diabetes Educator</i> , 2007, 33, 14S-19S.	2.6	3
125	Increasing Patient Acceptance and Adherence Toward Insulin. <i>Postgraduate Medicine</i> , 2016, 128, 11-20.	0.9	3
126	Treating diabetes: cardiovascular benefits of antidiabetes drugs. <i>American Journal of Managed Care</i> , 2002, 8, S219-28; quiz S229-32.	0.8	3



#	ARTICLE	IF	CITATIONS
127	Diagnosing diabetes in 2000. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2000, 7, 31-37.	0.6	2
128	Diabetes Disease Management: Past, Present, and Future. , 2001, 11, 86-93.		2
129	Do We Really Need Continuous Glucose Monitoring?. <i>Diabetes Technology and Therapeutics</i> , 2009, 11, S-128-S-130.	2.4	2
130	Considerations for treating dyslipidemia in special diabetic populations. <i>Diabetes/Metabolism Research and Reviews</i> , 2002, 18, 88-95.	1.7	1
131	Diabetes and Cardiovascular Disease Risk Factors as Influenced by Race and Ethnic Background. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	0.8	1
132	Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin-treated type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1752-1756.	2.2	1
133	Specialized Technology Education for Pumps & Pens in Underserved Populations with Diabetes (STEPP-UP). <i>Diabetes Technology and Therapeutics</i> , 2021, , .	2.4	1
134	Response to Comment on Wong et al. Real-Time Continuous Glucose Monitoring Among Participants in the T1D Exchange Clinic Registry. <i>Diabetes Care</i> 2014;37:2702â€“2709. <i>Diabetes Care</i> , 2015, 38, e61-e61.	4.3	1
135	Use of Glycosylated Hemoglobin Levels for Diagnosing Diabetes Mellitus-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1997, 277, 211.	3.8	0
136	Diagnosing diabetes in 2000. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2000, 7, 31-37.	0.6	0
137	Challenges in Applying Diabetes Technology to Clinical Care. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 849-850.	2.4	0
138	Managing Diabetes in the Middle-Aged Patient When Loss of Glycemic Control Occurs. <i>The Diabetes Educator</i> , 2012, 38, 13S-21S.	2.6	0
139	Authorsâ€™ reply to Bosco-LÃ©vy and Salvo. <i>BMJ, The</i> , 2016, 354, i4330.	3.0	0
140	Response to the comment on: â€œDulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A postâ€“hoc analysis of the AWARDâ€“2, â€“4 and â€“5 trialsâ€“. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2319-2320.	2.2	0
141	Running a Diabetes Clinic. , 2006, , 583-592.		0
142	Therapy of Type 1 Diabetes Mellitus. , 2010, , 709-729.		0
143	Therapy of Type 1 Diabetes Mellitus. , 2017, , 1-24.		0